This article's study endeavors to determine if p53 is responsible for cisplatin sensitization by NSC109268. Results have implications for sensitivity of ovarian cancer cells to cisplatin independent of p53.
UNT Health Science Center is one of the nation's premier graduate academic medical centers, with five schools that specialize in patient-centered education, research, and health care: Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, School of Public Health, School of Health Professions, and UNT System College of Pharmacy.
This article's study endeavors to determine if p53 is responsible for cisplatin sensitization by NSC109268. Results have implications for sensitivity of ovarian cancer cells to cisplatin independent of p53.
Physical Description
7 p.
Notes
Abstract: Background: Ovarian cancer is the leading cause of death among gynecological cancers. Cisplatin is one of the most effective anticancer drugs used in the treatment of ovarian cancer. Development of resistance to cisplatin limits its therapeutic use. Most of the anticancer drugs, including cisplatin, are believed to kill cancer cells by inducing apoptosis and a defect in apoptotic signaling can contribute to drug resistance. The tumor suppressor protein p53 plays a critical role in DNA damage-induced apoptosis. During a yeast-based drug screening, NSC109268 was identified to enhance cellular sensitivity to cisplatin. The objective of the present study is to determine if p53 is responsible for cisplatin sensitization by NSC109268. Results: NSC109268 enhanced sensitivity of ovarian cancer 2008 cells and its cisplatin resistant counterpart 2008/C13* cells which express wild-type p53. The potentiation of cisplatin sensitivity by NSC109268 was greater in 2008/C13* cells compared to 2008 cells. Cisplatin caused a concentration-dependent increase in p53 in 2008 and 2008/C13* cells, and the induction of p53 correlated with cisplatin-induced apoptosis as determined by the cleavage of PARP. NSC109268 alone had no effect on p53 but it enhanced p53 level in response to cisplatin. Knockdown of p53 by siRNA, however, did not attenuate cell death in response to cisplatin or combination of NSC109268 and cisplatin. Conclusions: These results demonstrate that NSC109268 enhances sensitivity of ovarian cancer 2008 cells to cisplatin independent of p53.
This article is part of the following collection of related materials.
UNT Scholarly Works
Materials from the UNT community's research, creative, and scholarly activities and UNT's Open Access Repository. Access to some items in this collection may be restricted.
Shankar, Eswar; Basu, Chandreyi; Adkins, Brett; Siede, Wolfram & Basu, Alakananda.NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner,
article,
October 5, 2010;
(https://digital.library.unt.edu/ark:/67531/metadc1838884/:
accessed April 25, 2024),
University of North Texas Libraries, UNT Digital Library, https://digital.library.unt.edu;
crediting UNT Health Science Center.
